Curevo Vaccine Email Format
Biotechnology ResearchWashington, United States11-50 Employees
Curevo Vaccine is a biotechnology research company that operates as a clinical-stage developer of vaccines targeting varicella and herpes zoster. It is headquartered in Bothell, Washington, at 21540 30th Drive Southeast, Suite 260, United States. Its lead product candidate, amezosvatein (CRV-101), is an adjuvanted subunit vaccine designed to prevent herpes zoster, with aims of non-inferior efficacy and improved reactogenicity relative to Shingrix. The company employs between 11 and 50 people. In May 2026, Eli Lilly acquired Curevo Vaccine for about $1.5 billion, marking a major development in the company's history.